Skip to content

Effect of Krishnavajrabhraka Bhasma [KVB] in Asthma

Experimental and clinical evaluation of standardized Krishnavajrabhraka Bhasma for its rasayan karma in Shwas vyadhi

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013084
Enrollment
54
Registered
2018-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic bronchial Asthma

Interventions

Intervention1: Krishna Vajrabhraka Bhasma [KVB] : 125 mg with honey thrice a day for 12 weeks Control Intervention1: Beclomethasone puff: 50 mcg twice a day for 12 weeks

Sponsors

Department of Indian System of Medicine Homoepathy AYUSH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I Ayurvedic parameters •Patients presenting with signs and symptoms of Tamak Shwas for equal to and more than one year as described in Ayurvedic texts. •Patients presenting with 3 or more of the following symptoms- i. Peenas ii. Ghurghurak iii. Aasya Udhvanasa iv. Kantha Udhvansa v.Vak Kricchrata vi. Lalat Sweda vii. Parshvagraha viii. Ushnabhiprayata ix. Aasya Shushkata x. Vepathu xi. Aruchi xii. Annadvesh II Modern medicine parameters Patients with bronchial asthma categorised as mild intermittent mild persistant moderate persistant

Exclusion criteria

Exclusion criteria: I Ayurvedic Parameters •Patients in whom â??Shwasâ?? is present as a Upadrava, Lakshan , Udarka, Poorvaroop and Arishta lakshan of other disease. •Patients in whom the onset of disease is less than one year •Patients with Shwas caused due to fatal injury of Urasthita Marma (Stanmool, Stanrohit, Aapalaap, Aapsthambh). •Patients with critical condition of Shwas. •Patients with Shwas which requires Shodhan such as Virechan or Vaman for therapeutic use II Modern medicine parameters Cases with co-existing pulmonary conditions. Acute respiratory tract infection. Requiring oral steroids. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
I-To assess improvement in Spirometric indices FEV1 by _ 200ml. II-Reduction in the number of acute attacks Reducing in the number of acute attacks. Timepoint: 9 months

Secondary

MeasureTime frame
Increase in duration between two consecutive acute attacks Decrease in severity of the attack Reduction in number of puffs per day Improvement in values of Peak flow meter Improvement in asthma symptom score throughout daytime point Timepoint: 9 months

Countries

India

Contacts

Public ContactDr Vijaya Pandit

Bharati Vidyapeeth (Deemed to be University), Pune, India

drvpandit@yahoo.co.in9371003390

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026